isoproterenol has been researched along with Cardiac Remodeling, Ventricular in 153 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The study aims to understand the effect of arbutin on isoproterenol (ISO)-induced cardiac hypertrophy in mice." | 7.96 | Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice. ( Alavala, S; Jerald, MK; Mir, SM; Nalban, N; Sangaraju, R; Sistla, R, 2020) |
| " acuta ameliorated cardiac function and inhibited isoproterenol (ISO)‑induced myocardial fibrosis in rats." | 7.96 | The aqueous extract of Gentianella acuta improves isoproterenol‑induced myocardial fibrosis via inhibition of the TGF‑β1/Smads signaling pathway. ( Li, AY; Li, YF; Liu, Y; Song, JN; Sun, JH; Xu, GR; Yang, HX; Zhang, C; Zhang, Y, 2020) |
| " This study evaluated whether LCZ696 affects left ventricular hypertrophy, fibrosis, and hemodynamics in isoproterenol (ISO)-treated rats compared with valsartan alone." | 7.91 | Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. ( Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M, 2019) |
| " Furthermore, the effects of 2-ME on blood pressure and cardiovascular remodeling in the constricted aorta (CA) rat model and on isoproterenol-induced (ISO) cardiac hypertrophy and fibrosis were examined." | 7.91 | 2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury. ( Bastacky, SI; Jackson, EK; Salah, E; Tofovic, SP, 2019) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 7.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| "Isoproterenol is used widely for inducing heart failure in mice." | 7.88 | Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation. ( Chang, SC; Rau, CD; Ren, S; Wang, JJ, 2018) |
| "To investigate the effect of dimethyl fumarate (DMF) on Toll-like receptor (TLR) signalling pathway in isoproterenol (ISO)-induced cardiac hypertrophy in rats." | 7.88 | Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model. ( Ahmed, AA; Ahmed, AAE; El Morsy, EM; Nofal, S, 2018) |
| "To evaluate the effect of oltipraz (OPZ) on isoproterenol-induced heart failure (HF) and heart function." | 7.88 | Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. ( Guo, M; Hao, MH; Ma, XY; Sun, WP; Tang, Y; Zhu, HY, 2018) |
| "Low-dose rosuvastatin exerted cardioprotective effects on isoproterenol-induced heart failure in rats by modulating DDAH-ADMA-NO pathway, and it may present the new therapeutic value in ameliorating chronic heart failure." | 7.85 | Protective effects of low-dose rosuvastatin on isoproterenol-induced chronic heart failure in rats by regulation of DDAH-ADMA-NO pathway. ( Ma, P; Wang, Y; Xiong, A; Xu, Q; Xu, Y; Zhou, R, 2017) |
| "We previously reported a genetic analysis of heart failure traits in a population of inbred mouse strains treated with isoproterenol to mimic catecholamine-driven cardiac hypertrophy." | 7.85 | Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. ( Karma, A; Lusis, AJ; Rau, CD; Ren, S; Romay, MC; Santolini, M; Tuteryan, M; Wang, JJ; Wang, Y; Weiss, JN, 2017) |
| "This study aimed to evaluate the antithrombotic, anti-inflammatory and anti-cardiac remodeling properties of eugenol in isoproterenol-induced myocardial infarction in rats." | 7.83 | Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat. ( Allouche, N; Derbali, F; Ellefi, H; Gammoudi, A; Gharsallah, N; Hajji, R; Kadri, A; Khabbabi, G; Mnafgui, K, 2016) |
| "The present study aimed to investigate the cardioprotective effect of hydroxytyrosol (HT) against isoproterenol-induced myocardial infarction in rats." | 7.83 | Protective Effect of Hydroxytyrosol Against Cardiac Remodeling After Isoproterenol-Induced Myocardial Infarction in Rat. ( Allouche, N; Derbali, F; Elfeki, A; Ellefi, H; Gharsallah, N; Hajji, R; Khlif, I; Kraiem, F; Mnafgui, K, 2016) |
| "We aimed to understand the genetic control of cardiac remodeling using an isoproterenol-induced heart failure model in mice, which allowed control of confounding factors in an experimental setting." | 7.83 | Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. ( Avetisyan, R; Gong, KW; Lusis, AJ; Rau, C; Ren, S; Romay, MC; Stolin, G; Wang, JJ; Wang, Y, 2016) |
| "This study aimed to explore the effects of puerarin on autophagy in cardiac hypertrophy." | 7.81 | Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. ( Chen, M; Huang, Z; Li, Y; Liu, B; Liu, P; Luo, C; Ou, C; Wu, Z; Zhang, J, 2015) |
| "Oleuropein offers high preventive effects from cardiac remodeling process in rats with acute myocardial infarction." | 7.81 | Preventive effects of oleuropein against cardiac remodeling after myocardial infarction in Wistar rat through inhibiting angiotensin-converting enzyme activity. ( Allouche, N; Derbali, F; Elfeki, A; Ellefi, H; Gharsallah, N; Hajji, R; Halabalaki, M; Khlif, I; Kraiem, F; Michel, T; Mnafgui, K; Skaltsounis, AL, 2015) |
| "The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood." | 7.80 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014) |
| " Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury." | 7.79 | The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. ( Almeida, AP; Beiman, M; Carvalho, MB; Cohen, Y; Cojocaru, G; Ferreira, AJ; Ianzer, D; Marques, FD; Peluso, AA; Rotman, G; Santos, RA; Savergnini, SQ; Silva, GA, 2013) |
| "Icariin ameliorates left ventricular dysfunction and cardiac remodelling through down-regulating matrix metalloproteinase-2 and 9 activity and myocardial apoptosis in rats with congestive heart failure." | 7.77 | Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. ( Cai, H; Cao, SP; Gu, N; Qian, CF; Song, YH; Zhao, ZM, 2011) |
| "Rats were injected with ISO to induce cardiac hypertrophy and treated with MCP." | 5.62 | Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway. ( Li, AY; Li, Y; Liu, WZ; Liu, XC; Song, QH; Sun, JH; Xu, GR; Yang, HX; Zhang, C; Zhang, Y; Zhou, WW, 2021) |
| "Insulin resistance was induced by HFrHFD feeding for 16 weeks." | 5.62 | Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2021) |
| "Cardiac fibrosis is a crucial aspect of cardiac remodeling that can severely affect cardiac function." | 5.51 | Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. ( Che, Y; Jin, YG; Shen, DF; Wang, SS; Wang, ZP; Wu, QQ; Yuan, Y, 2019) |
| "Cardiac fibrosis is a significant global health problem with limited treatment choices." | 5.46 | Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model. ( Chen, GX; Fan, T; Hou, J; Liang, MY; Wang, LX; Wu, ZK; Yang, X; Yue, Y, 2017) |
| " In this study, we observed the high expression of MBNL1 in cardiac tissue and peripheral blood of an isoproterenol (ISO)-induced cardiac hypertrophy mouse model." | 4.02 | MBNL1 regulates isoproterenol-induced myocardial remodelling in vitro and in vivo. ( Liang, C; Luo, Y; Xu, Y; Zhang, T, 2021) |
| " We determined that the knockout of WWP2 specifically in myocardium decreased the level of PARP1 ubiquitination and increased the effects of isoproterenol (ISO)-induced PARP1 and PARylation, in turn aggravating ISO-induced myocardial hypertrophy, heart failure, and myocardial fibrosis." | 3.96 | Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling. ( Cao, L; Qian, H; Sun, Y; Wu, S; Zhang, N; Zhang, Y, 2020) |
| " The study aims to understand the effect of arbutin on isoproterenol (ISO)-induced cardiac hypertrophy in mice." | 3.96 | Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice. ( Alavala, S; Jerald, MK; Mir, SM; Nalban, N; Sangaraju, R; Sistla, R, 2020) |
| " acuta ameliorated cardiac function and inhibited isoproterenol (ISO)‑induced myocardial fibrosis in rats." | 3.96 | The aqueous extract of Gentianella acuta improves isoproterenol‑induced myocardial fibrosis via inhibition of the TGF‑β1/Smads signaling pathway. ( Li, AY; Li, YF; Liu, Y; Song, JN; Sun, JH; Xu, GR; Yang, HX; Zhang, C; Zhang, Y, 2020) |
| " Furthermore, the effects of 2-ME on blood pressure and cardiovascular remodeling in the constricted aorta (CA) rat model and on isoproterenol-induced (ISO) cardiac hypertrophy and fibrosis were examined." | 3.91 | 2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury. ( Bastacky, SI; Jackson, EK; Salah, E; Tofovic, SP, 2019) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 3.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| " This study evaluated whether LCZ696 affects left ventricular hypertrophy, fibrosis, and hemodynamics in isoproterenol (ISO)-treated rats compared with valsartan alone." | 3.91 | Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. ( Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M, 2019) |
| " Hence, the aim of this study was to describe alterations in and show potential correlations between the structural characteristics and the molecular and biochemical markers of cardiac remodelling on a model of isoproterenol-induced heart failure." | 3.91 | Relations between markers of cardiac remodelling and left ventricular collagen in an isoproterenol-induced heart damage model. ( Adamcova, M; Aziriova, S; Baka, T; Dolezelova, E; Karesova, I; Krajcirovicova, K; Repova, K; Simko, F; Stanko, P, 2019) |
| "To investigate the effect of dimethyl fumarate (DMF) on Toll-like receptor (TLR) signalling pathway in isoproterenol (ISO)-induced cardiac hypertrophy in rats." | 3.88 | Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model. ( Ahmed, AA; Ahmed, AAE; El Morsy, EM; Nofal, S, 2018) |
| "To evaluate the effect of oltipraz (OPZ) on isoproterenol-induced heart failure (HF) and heart function." | 3.88 | Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. ( Guo, M; Hao, MH; Ma, XY; Sun, WP; Tang, Y; Zhu, HY, 2018) |
| "Isoproterenol is used widely for inducing heart failure in mice." | 3.88 | Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation. ( Chang, SC; Rau, CD; Ren, S; Wang, JJ, 2018) |
| "We previously reported a genetic analysis of heart failure traits in a population of inbred mouse strains treated with isoproterenol to mimic catecholamine-driven cardiac hypertrophy." | 3.85 | Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. ( Karma, A; Lusis, AJ; Rau, CD; Ren, S; Romay, MC; Santolini, M; Tuteryan, M; Wang, JJ; Wang, Y; Weiss, JN, 2017) |
| "Low-dose rosuvastatin exerted cardioprotective effects on isoproterenol-induced heart failure in rats by modulating DDAH-ADMA-NO pathway, and it may present the new therapeutic value in ameliorating chronic heart failure." | 3.85 | Protective effects of low-dose rosuvastatin on isoproterenol-induced chronic heart failure in rats by regulation of DDAH-ADMA-NO pathway. ( Ma, P; Wang, Y; Xiong, A; Xu, Q; Xu, Y; Zhou, R, 2017) |
| "We aimed to understand the genetic control of cardiac remodeling using an isoproterenol-induced heart failure model in mice, which allowed control of confounding factors in an experimental setting." | 3.83 | Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model. ( Avetisyan, R; Gong, KW; Lusis, AJ; Rau, C; Ren, S; Romay, MC; Stolin, G; Wang, JJ; Wang, Y, 2016) |
| "The present study aimed to investigate the cardioprotective effect of hydroxytyrosol (HT) against isoproterenol-induced myocardial infarction in rats." | 3.83 | Protective Effect of Hydroxytyrosol Against Cardiac Remodeling After Isoproterenol-Induced Myocardial Infarction in Rat. ( Allouche, N; Derbali, F; Elfeki, A; Ellefi, H; Gharsallah, N; Hajji, R; Khlif, I; Kraiem, F; Mnafgui, K, 2016) |
| "This study aimed to evaluate the antithrombotic, anti-inflammatory and anti-cardiac remodeling properties of eugenol in isoproterenol-induced myocardial infarction in rats." | 3.83 | Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat. ( Allouche, N; Derbali, F; Ellefi, H; Gammoudi, A; Gharsallah, N; Hajji, R; Kadri, A; Khabbabi, G; Mnafgui, K, 2016) |
| " In a cardiac specific transgenic mouse model, it was observed that overexpression of hHole specifically in heart attenuated cardiac hypertrophy and fibrosis induced by isoproterenol (ISO), with blunted transcriptions of ERK1/2, total ERK1/2 proteins and phosphorylated ERK1/2 (p-ERK1/2) levels." | 3.83 | Cardiac Specific Overexpression of hHole Attenuates Isoproterenol-Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling. ( Cao, L; Chen, F; Dai, G; Deng, Y; Fan, X; Jiang, Z; Li, Y; Liu, X; Luo, S; Mo, X; Peng, X; Shi, Y; Wan, Y; Wang, X; Wang, Y; Wu, X; Xu, W; Ye, X; Yuan, W; Zeng, Q; Zhang, S; Zhou, J; Zhu, X, 2016) |
| "This study aimed to explore the effects of puerarin on autophagy in cardiac hypertrophy." | 3.81 | Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. ( Chen, M; Huang, Z; Li, Y; Liu, B; Liu, P; Luo, C; Ou, C; Wu, Z; Zhang, J, 2015) |
| "Oleuropein offers high preventive effects from cardiac remodeling process in rats with acute myocardial infarction." | 3.81 | Preventive effects of oleuropein against cardiac remodeling after myocardial infarction in Wistar rat through inhibiting angiotensin-converting enzyme activity. ( Allouche, N; Derbali, F; Elfeki, A; Ellefi, H; Gharsallah, N; Hajji, R; Halabalaki, M; Khlif, I; Kraiem, F; Michel, T; Mnafgui, K; Skaltsounis, AL, 2015) |
| "The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood." | 3.80 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014) |
| " Chronic injection with the β-adrenoceptor (β-AR) agonist isoproterenol (ISO) has been commonly used as an animal model of β-AR-induced cardiac remodelling and heart failure." | 3.80 | Echocardiographic assessment of β-adrenoceptor stimulation-induced heart failure with reduced heart rate in mice. ( Chen, C; Li, H; Lu, ZZ; Song, Y; Xiao, H; Zhang, YY, 2014) |
| " miR-22-null hearts blunted cardiac hypertrophy and cardiac remodeling in response to 2 independent stressors: isoproterenol infusion and an activated calcineurin transgene." | 3.79 | MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. ( Chen, J; Hu, X; Huang, ZP; Kataoka, M; Seok, HY; Wang, DZ; Zhang, Z, 2013) |
| " Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury." | 3.79 | The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. ( Almeida, AP; Beiman, M; Carvalho, MB; Cohen, Y; Cojocaru, G; Ferreira, AJ; Ianzer, D; Marques, FD; Peluso, AA; Rotman, G; Santos, RA; Savergnini, SQ; Silva, GA, 2013) |
| "Cardiac hypertrophy was induced by a chronic infusion of isoproterenol (ISO) 15 mg/kg/day for 3 weeks in human apoB transgenic mice (n = 9) and in non-transgenic wild-type mice (n = 10)." | 3.78 | Overexpression of apolipoprotein B attenuates pathologic cardiac remodeling and hypertrophy in response to catecholamines and after myocardial infarction in mice. ( Borén, J; Lindbom, M; Omerovic, E; Råmunddal, T; Shao, Y; Täng, MS, 2012) |
| "Cardiac hypertrophy was induced in wild-type and IL-10 knockout mice by isoproterenol (ISO) infusion." | 3.78 | Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB. ( Barefield, D; Ghosh, AK; Gupta, R; Hoxha, E; Kishore, R; Krishnamurthy, P; Lambers, E; Mackie, A; Qin, G; Ramirez, V; Sadayappan, S; Singh, N; Thal, M; Verma, SK, 2012) |
| "Icariin ameliorates left ventricular dysfunction and cardiac remodelling through down-regulating matrix metalloproteinase-2 and 9 activity and myocardial apoptosis in rats with congestive heart failure." | 3.77 | Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. ( Cai, H; Cao, SP; Gu, N; Qian, CF; Song, YH; Zhao, ZM, 2011) |
| " Moreover, the PDE1 inhibitor attenuated isoproterenol-induced interstitial fibrosis in mice." | 3.77 | Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. ( Cai, Y; Dostmann, WR; Fujiwara, K; Miller, CL; Oikawa, M; Thomas, T; Yan, C; Zaccolo, M, 2011) |
| " We found that, in the left ventricle, Gal-3 1) enhanced macrophage and mast cell infiltration, increased cardiac interstitial and perivascular fibrosis, and causes cardiac hypertrophy; 2) increased TGF-beta expression and Smad3 phosphorylation; and 3) decreased negative change in pressure over time response to isoproterenol challenge, ratio of early left ventricular filling phase to atrial contraction phase, and left ventricular ejection fraction." | 3.75 | N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. ( André, S; Carretero, OA; D'Ambrosio, M; Gabius, HJ; Liao, TD; Liu, YH; Peng, H; Rhaleb, NE; Sharma, U, 2009) |
| " A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction." | 3.73 | PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. ( Deres, P; Gallyas, F; Halmosi, R; Hanto, K; Hideg, K; Kalai, T; Kulcsar, G; Palfi, A; Sumegi, B; Szabados, E; Szereday, Z; Toth, A; Toth, K, 2006) |
| "The role of renin-angiotensin-aldosterone system in cardiac remodelling was studied in isoproterenol-induced cardiac hypertrophy in rats." | 3.71 | Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. ( Casis, O; Echevarria, E; Espiña, L; Gallego, M; Iriarte, MM; Vegas, L, 2001) |
| "The in vivo signal transduction pathway, responsible for isoproterenol-induced cardiac hypertrophy or remodeling, remains to be clarified." | 3.70 | Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling. ( Izumi, Y; Kim, S; Komatsu, R; Omura, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1999) |
| "We administered oral metoprolol or no therapy to rats for 12 weeks after large myocardial infarction and subsequently examined left ventricular (LV) remodeling; myocardial tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 expression; and NO." | 3.70 | beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. ( Chandrasekar, B; Freeman, GL; Murray, DR; Prabhu, SD, 2000) |
| "Engeletin is a potent natural compound with antioxidant and anti-inflammatory properties." | 1.91 | Engeletin mediates antiarrhythmic effects in mice with isoproterenol-induced cardiac remodeling. ( Fang, Z; Jiang, X; Liu, Z; Tao, B, 2023) |
| "Echinacoside (ECH) is a natural phenylethanoid glycoside and is the major active component of traditional Chinese medicine Cistanches Herba, which is reported to possess powerful anti-oxidation and anti-inflammatory effects." | 1.72 | Echinacoside inhibited cardiomyocyte pyroptosis and improved heart function of HF rats induced by isoproterenol via suppressing NADPH/ROS/ER stress. ( Bai, H; Duan, Y; Luan, C; Ni, Y; Zhang, J; Zhu, W, 2022) |
| "Insulin resistance was induced by HFrHFD feeding for 16 weeks." | 1.62 | Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2021) |
| "Rats were injected with ISO to induce cardiac hypertrophy and treated with MCP." | 1.62 | Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway. ( Li, AY; Li, Y; Liu, WZ; Liu, XC; Song, QH; Sun, JH; Xu, GR; Yang, HX; Zhang, C; Zhang, Y; Zhou, WW, 2021) |
| "Cardiac fibrosis is a crucial aspect of cardiac remodeling that can severely affect cardiac function." | 1.51 | Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. ( Che, Y; Jin, YG; Shen, DF; Wang, SS; Wang, ZP; Wu, QQ; Yuan, Y, 2019) |
| "Hypertension is a major cause of left ventricular (LV) diastolic dysfunction." | 1.48 | Limited Impact of β-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease. ( Bamaiyi, AJ; Mojiminiyi, FB; Norman, G; Norton, GR; Peterson, V; Woodiwiss, AJ, 2018) |
| "Cardiac fibrosis is a significant global health problem with limited treatment choices." | 1.46 | Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model. ( Chen, GX; Fan, T; Hou, J; Liang, MY; Wang, LX; Wu, ZK; Yang, X; Yue, Y, 2017) |
| "ISO-induced cardiac hypertrophy, characterized by an increase in the heart weight/body weight ratio, CSA and ventricular wall thickness." | 1.46 | Specific α7 nicotinic acetylcholine receptor agonist ameliorates isoproterenol-induced cardiac remodelling in mice through TGF-β1/Smad3 pathway. ( Fang, HL; He, X; Li, DL; Liu, JJ; Lu, Y; Sun, L; Wang, S; Wei, XL; Yang, YH; Yu, XJ; Zang, WJ; Zhang, N; Zhao, M, 2017) |
| "Triptolide (TPL) is a diterpene triepoxide with potent immunosuppressive and anti-inflammatory properties." | 1.42 | Triptolide alleviates isoprenaline-induced cardiac remodeling in rats via TGF-β1/Smad3 and p38 MAPK signaling pathway. ( Chen, J; Huang, D; Huang, Y; Ke, J; Li, L; Liu, M; Wu, W, 2015) |
| "No mouse showed ventricular arrhythmias in all of the 4 groups." | 1.42 | [Combined transgenic inhibition of CaMKII and Ik1 on cardiac remodeling]. ( Cui, TP; Dai, M; Du, XL; Du, YM; Huang, Y; Li, JD; Shu, YW; Su, GH; Yao, YF; Zhang, JM, 2015) |
| "Hypertrophy was restored on NOS or protein kinase G inhibition." | 1.40 | Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. ( Balligand, JL; Beauloye, C; Belge, C; Bertrand, L; Dessy, C; Dubois-Deruy, E; Esfahani, H; Götz, KR; Hamelet, J; Hammond, J; Herijgers, P; Hilfiker-Kleiner, D; Iaccarino, G; Jnaoui, K; Langin, D; Lobysheva, I; Manoury, B; Markl, A; Nikolaev, VO; Pouleur, AC; Tavernier, G; Vanderper, A, 2014) |
| "The characteristics of ventricular remodeling in model group included that the heart weight index, myocyte cross-sectional area, myocardial fibrosis, and the hydroxyproline content in cardiac tissue were all increased significantly." | 1.39 | [Effects of ATP-sensitive potassium channel opener iptakalim against ventricular remodeling and its mechanisms of endothelial protection]. ( Cui, WY; Duan, L; Long, CL; Wang, H; Zhang, YF; Zhong, ML; Zhou, HM, 2013) |
| "Isoproterenol was given subcutaneously (1 mg/kg, twice per day for 7 d) to induce ventricular remodeling in mice." | 1.38 | [Effects of a compound Chinese medicine Xinji' erkang on isoproterenol-induced ventricular remodeling in mice]. ( Du, SM; Gao, S; Guo, YW; Huang, LL; Jia, Y; Wang, J; Wang, XH; Yu, TT, 2012) |
| "AV block was created in dogs to induce ventricular remodeling, including enhanced susceptibility to dofetilide-induced torsades de pointes arrhythmias." | 1.38 | Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog. ( Antoons, G; Beekman, JD; Bourgonje, VJ; de Windt, LJ; Houtman, MJ; Miedema, LF; Schoenmakers, M; Sipido, K; van der Nagel, R; van Veen, TA; Vos, MA, 2012) |
| "Leonurus at a dosage of 16 g/kg may improve the systolic function; Leonurus at a dosage of 8 g/kg may improve the diastolic function, down-regulate the expression of collagen and normalize the ratio of I/III collagen." | 1.37 | [Protective effects of Leonurus japonicas on myocardial remodeling induced by isoproterenol in rats]. ( Gu, YP; Guo, W; Liu, Y; Lv, R; Wei, HC; Yuan, BP; Zhang, C, 2011) |
| " Isoprenaline (ISO), a β-adrenoceptor agonist, was infused at variable dosage and duration using either subcutaneously implanted osmotic minipumps or daily injections, in an attempt to establish the relevant treatment protocol." | 1.37 | Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation. ( Olesen, SP; Osadchii, OE; Soltysinska, E, 2011) |
| " Experimentally, chronic administration of the β-AR agonist isoproterenol (ISO) has been most commonly used to model β-AR-induced cardiac remodeling." | 1.37 | Distinct actions of intermittent and sustained β-adrenoceptor stimulation on cardiac remodeling. ( Chen, C; Fu, Y; Li, Z; Ma, X; Shen, Q; Song, Y; Zhang, Y, 2011) |
| "Mast cells are increased in isolated mitral regurgitation (MR) in the dog and may mediate extracellular matrix loss and left ventricular (LV) dilatation." | 1.36 | Mast cell stabilization decreases cardiomyocyte and LV function in dogs with isolated mitral regurgitation. ( Chen, Y; Dell'italia, LJ; Denney, T; Desai, R; Dillon, AR; Gladden, JD; Gupta, H; Killingsworth, C; Pat, B; Powell, PC; Tillson, M; Walcott, G, 2010) |
| "The ventricular remodeling of mice were induced by subcutaneous injection of ISO with the dosage of 2 mg/kg daily for 7 d and the rats with L-Thy intraperitoneally with the dosage of 0." | 1.36 | [Effect of Chrysanthemum indicum on ventricular remodeling in rats]. ( Chen, CX; Gao, JP; Gu, WL; Lv, J; Wan, Y; Wu, Q, 2010) |
| "Moreover, scar size was significantly smaller (16 +/- 6% vs." | 1.32 | Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction. ( Fuke, S; Kohno, M; Kondo, I; Namba, T; Noma, T; Ohmori, K; Oshita, A; Shinomiya, K; Takeuchi, H, 2004) |
| "The transition from compensated left ventricular hypertrophy (LVH) to heart failure is associated with alterations in the myocardial interstitium." | 1.31 | Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. ( Chung, ES; Lancaster, EJ; Mela, T; Meyer, TE; Norton, GR; Sprott, S; Tsotetsi, OJ; Woodiwiss, AJ, 2001) |
| " Thus, it is necessary to titrate the dosage of carvedilol, it should be initiated at less than 0." | 1.31 | Cardiovascular and renal effects of carvedilol in dogs with heart failure. ( Ishikawa, Y; Sasaki, T; Uechi, M; Ueno, K; Yamamoto, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.31) | 18.2507 |
| 2000's | 34 (22.22) | 29.6817 |
| 2010's | 86 (56.21) | 24.3611 |
| 2020's | 31 (20.26) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 9 |
| Shang, Z | 1 |
| Liu, A | 1 |
| Flamant, M | 1 |
| Mougenot, N | 1 |
| Balse, E | 1 |
| Le Fèvre, L | 1 |
| Atassi, F | 1 |
| Gautier, EL | 1 |
| Le Goff, W | 1 |
| Keck, M | 1 |
| Nadaud, S | 1 |
| Combadière, C | 1 |
| Boissonnas, A | 1 |
| Pavoine, C | 1 |
| Li, Y | 5 |
| Zhou, WW | 1 |
| Sun, JH | 2 |
| Yang, HX | 2 |
| Xu, GR | 2 |
| Song, QH | 1 |
| Zhang, C | 4 |
| Liu, WZ | 1 |
| Liu, XC | 1 |
| Li, AY | 2 |
| Ibrahim, WS | 1 |
| Ahmed, HMS | 1 |
| Mahmoud, AAA | 1 |
| Mahmoud, MF | 1 |
| Ibrahim, IAAE | 1 |
| Peterson, VR | 1 |
| Norton, GR | 10 |
| Madziva, MT | 1 |
| Makaula, S | 1 |
| Yáñez-Bisbe, L | 1 |
| Garcia-Elias, A | 1 |
| Tajes, M | 1 |
| Almendros, I | 1 |
| Rodríguez-Sinovas, A | 1 |
| Inserte, J | 1 |
| Ruiz-Meana, M | 1 |
| Farré, R | 1 |
| Farré, N | 1 |
| Benito, B | 1 |
| Chen, X | 1 |
| Wan, W | 1 |
| Ran, Q | 1 |
| Ye, T | 1 |
| Sun, Y | 2 |
| Liu, Z | 2 |
| Liu, X | 3 |
| Shi, S | 1 |
| Qu, C | 1 |
| Yang, B | 1 |
| Jiang, XY | 1 |
| Guan, FF | 1 |
| Ma, JX | 1 |
| Dong, W | 1 |
| Qi, XL | 1 |
| Zhang, X | 2 |
| Chen, W | 1 |
| Gao, S | 4 |
| Gao, X | 1 |
| Pan, S | 1 |
| Wang, JZ | 1 |
| Ma, YW | 1 |
| Zhang, LF | 1 |
| Lu, D | 1 |
| Ni, Y | 2 |
| Zhang, J | 7 |
| Zhu, W | 2 |
| Duan, Y | 1 |
| Bai, H | 2 |
| Luan, C | 1 |
| Lunardon, G | 1 |
| de Oliveira Silva, T | 1 |
| Lino, CA | 1 |
| Lu, YW | 1 |
| Miranda, JB | 1 |
| Asprino, PF | 1 |
| de Almeida Silva, A | 1 |
| Nepomuceno, GT | 1 |
| Irigoyen, MCC | 1 |
| Carneiro-Ramos, MS | 1 |
| Takano, APC | 1 |
| Martinho, HDS | 1 |
| Barreto-Chaves, MLM | 1 |
| Wang, DZ | 2 |
| Diniz, GP | 1 |
| Cheng, M | 1 |
| Chen, C | 4 |
| Yu, K | 1 |
| Lv, X | 1 |
| Zeng, Q | 2 |
| Dong, N | 1 |
| Zhu, F | 1 |
| Qian, J | 2 |
| Liang, S | 1 |
| Wang, Q | 1 |
| Xu, J | 1 |
| Huang, W | 1 |
| Wu, G | 1 |
| Liang, G | 1 |
| Fang, Z | 1 |
| Tao, B | 1 |
| Jiang, X | 1 |
| Zhao, Y | 1 |
| Zhao, X | 1 |
| Diao, J | 1 |
| Jia, S | 1 |
| Feng, P | 1 |
| Yu, P | 1 |
| Cheng, G | 1 |
| Nalban, N | 1 |
| Sangaraju, R | 1 |
| Alavala, S | 1 |
| Mir, SM | 1 |
| Jerald, MK | 1 |
| Sistla, R | 1 |
| Che, Y | 1 |
| Shen, DF | 1 |
| Wang, ZP | 1 |
| Jin, YG | 1 |
| Wu, QQ | 1 |
| Wang, SS | 1 |
| Yuan, Y | 1 |
| Yuan, YH | 1 |
| Xia, XH | 1 |
| He, XH | 1 |
| Liu, LP | 1 |
| Wang, S | 3 |
| Hu, C | 1 |
| Liu, ZY | 1 |
| Zuo, Z | 1 |
| Ji, MY | 1 |
| Zhao, K | 1 |
| Su, ZP | 1 |
| Li, P | 2 |
| Hou, DR | 1 |
| Song, JN | 1 |
| Li, YF | 1 |
| Liu, Y | 2 |
| Zhang, N | 3 |
| Qian, H | 1 |
| Wu, S | 1 |
| Cao, L | 2 |
| Sun, D | 1 |
| Zhang, F | 1 |
| Ma, T | 1 |
| Liang, Z | 1 |
| Karam, S | 1 |
| Margaria, JP | 1 |
| Bourcier, A | 1 |
| Mika, D | 1 |
| Varin, A | 1 |
| Bedioune, I | 1 |
| Lindner, M | 1 |
| Bouadjel, K | 1 |
| Dessillons, M | 1 |
| Gaudin, F | 1 |
| Lefebvre, F | 1 |
| Mateo, P | 1 |
| Lechène, P | 1 |
| Gomez, S | 1 |
| Domergue, V | 1 |
| Robert, P | 1 |
| Coquard, C | 1 |
| Algalarrondo, V | 1 |
| Samuel, JL | 1 |
| Michel, JB | 1 |
| Charpentier, F | 1 |
| Ghigo, A | 1 |
| Hirsch, E | 1 |
| Fischmeister, R | 1 |
| Leroy, J | 1 |
| Vandecasteele, G | 1 |
| Feng, L | 1 |
| Li, G | 1 |
| An, J | 1 |
| Zhang, S | 2 |
| Li, J | 3 |
| Liu, J | 2 |
| Ren, J | 1 |
| Yang, L | 1 |
| Qi, Z | 1 |
| Nishimura, K | 1 |
| Asakura, M | 1 |
| Hirotani, S | 1 |
| Okuhara, Y | 1 |
| Shirai, M | 1 |
| Orihara, Y | 1 |
| Matsumoto, Y | 1 |
| Naito, Y | 1 |
| Minamino, N | 1 |
| Masuyama, T | 1 |
| Ishihara, M | 1 |
| Wang, HB | 1 |
| Yang, J | 2 |
| Shuai, W | 1 |
| Liu, LB | 1 |
| Xu, M | 1 |
| Tang, QZ | 1 |
| Simko, F | 2 |
| Baka, T | 2 |
| Repova, K | 2 |
| Aziriova, S | 2 |
| Krajcirovicova, K | 2 |
| Paulis, L | 1 |
| Adamcova, M | 2 |
| Sun, TL | 1 |
| Li, WQ | 1 |
| Tong, XL | 1 |
| Liu, XY | 2 |
| Zhou, WH | 1 |
| Takahara, S | 1 |
| Ferdaoussi, M | 1 |
| Srnic, N | 1 |
| Maayah, ZH | 1 |
| Soni, S | 1 |
| Migglautsch, AK | 1 |
| Breinbauer, R | 1 |
| Kershaw, EE | 1 |
| Dyck, JRB | 1 |
| Xu, Y | 2 |
| Liang, C | 1 |
| Luo, Y | 1 |
| Zhang, T | 1 |
| Deng, J | 1 |
| Li, Q | 1 |
| Chen, Y | 3 |
| Pan, R | 1 |
| Liang, T | 1 |
| Guo, J | 1 |
| Sun, T | 1 |
| Fu, X | 1 |
| Wang, L | 1 |
| Zhang, L | 1 |
| Werhahn, SM | 1 |
| Kreusser, JS | 1 |
| Hagenmüller, M | 1 |
| Beckendorf, J | 1 |
| Diemert, N | 1 |
| Hoffmann, S | 1 |
| Schultz, JH | 1 |
| Backs, J | 1 |
| Dewenter, M | 1 |
| Tanner, MA | 1 |
| Maitz, CA | 1 |
| Grisanti, LA | 2 |
| Ulla, A | 1 |
| Mohamed, MK | 1 |
| Sikder, B | 1 |
| Rahman, AT | 1 |
| Sumi, FA | 1 |
| Hossain, M | 1 |
| Reza, HM | 1 |
| Rahman, GMS | 1 |
| Alam, MA | 1 |
| Wang, LX | 1 |
| Yang, X | 1 |
| Yue, Y | 1 |
| Fan, T | 1 |
| Hou, J | 1 |
| Chen, GX | 1 |
| Liang, MY | 1 |
| Wu, ZK | 1 |
| Yang, YH | 1 |
| Fang, HL | 1 |
| Zhao, M | 1 |
| Wei, XL | 1 |
| Lu, Y | 1 |
| Yu, XJ | 1 |
| Sun, L | 1 |
| He, X | 1 |
| Li, DL | 1 |
| Liu, JJ | 1 |
| Zang, WJ | 1 |
| Rathinavel, A | 1 |
| Sankar, J | 1 |
| Mohammed Sadullah, SS | 1 |
| Niranjali Devaraj, S | 1 |
| Wang, XD | 1 |
| Qi, XX | 1 |
| Bian, Y | 1 |
| Chen, XD | 1 |
| Zhang, YY | 3 |
| Fang, ZY | 1 |
| Ivey, MJ | 1 |
| Kuwabara, JT | 1 |
| Pai, JT | 1 |
| Moore, RE | 1 |
| Sun, Z | 1 |
| Tallquist, MD | 1 |
| Cui, XH | 1 |
| Wang, HL | 1 |
| Wu, R | 1 |
| Yao, PA | 1 |
| Wei, KZ | 1 |
| Gao, JP | 3 |
| Miyoshi, T | 1 |
| Nakamura, K | 1 |
| Miura, D | 1 |
| Yoshida, M | 1 |
| Saito, Y | 1 |
| Akagi, S | 1 |
| Ohno, Y | 1 |
| Kondo, M | 1 |
| Ito, H | 2 |
| Chang, SC | 1 |
| Ren, S | 3 |
| Rau, CD | 2 |
| Wang, JJ | 3 |
| McClatchy, DB | 1 |
| Ma, Y | 1 |
| Liem, DA | 1 |
| Ng, DCM | 1 |
| Ping, P | 1 |
| Yates, JR | 1 |
| Ali, SS | 1 |
| Mohamed, SFA | 1 |
| Rozalei, NH | 1 |
| Boon, YW | 1 |
| Zainalabidin, S | 1 |
| Lu, F | 1 |
| Yu, H | 1 |
| Li, ZH | 1 |
| Dong, WR | 1 |
| Liu, SM | 1 |
| Pinotti, MF | 1 |
| Matias, AM | 1 |
| Sugizaki, MM | 1 |
| Nascimento, AFD | 1 |
| Pai, MD | 1 |
| Leopoldo, APL | 1 |
| Cicogna, AC | 1 |
| Leopoldo, AS | 1 |
| Ahmed, AA | 1 |
| Ahmed, AAE | 1 |
| El Morsy, EM | 1 |
| Nofal, S | 1 |
| Puhl, SL | 1 |
| Weeks, KL | 1 |
| Güran, A | 1 |
| Ranieri, A | 1 |
| Boknik, P | 1 |
| Kirchhefer, U | 1 |
| Müller, FU | 1 |
| Avkiran, M | 1 |
| Bamaiyi, AJ | 1 |
| Peterson, V | 1 |
| Norman, G | 1 |
| Mojiminiyi, FB | 1 |
| Woodiwiss, AJ | 9 |
| Tang, Y | 1 |
| Guo, M | 1 |
| Ma, XY | 1 |
| Sun, WP | 1 |
| Hao, MH | 1 |
| Zhu, HY | 1 |
| Ishizue, N | 1 |
| Niwano, S | 1 |
| Niwano, H | 1 |
| Oikawa, J | 1 |
| Nakamura, H | 1 |
| Hashikata, T | 1 |
| Igarashi, T | 1 |
| Fujiishi, T | 1 |
| Yoshizawa, T | 1 |
| Kishihara, J | 1 |
| Satoh, A | 1 |
| Fukaya, H | 1 |
| Ako, J | 1 |
| Salah, E | 1 |
| Bastacky, SI | 1 |
| Jackson, EK | 1 |
| Tofovic, SP | 1 |
| Nakata, TM | 1 |
| Suzuki, K | 1 |
| Uemura, A | 1 |
| Shimada, K | 1 |
| Tanaka, R | 1 |
| Zou, J | 1 |
| Ma, W | 1 |
| Littlejohn, R | 1 |
| Stansfield, BK | 1 |
| Kim, IM | 1 |
| Zhou, J | 2 |
| Weintraub, NL | 1 |
| Su, H | 1 |
| Dolezelova, E | 1 |
| Karesova, I | 1 |
| Stanko, P | 1 |
| Moradi, F | 1 |
| Imani, AR | 1 |
| Faghihi, M | 1 |
| Morishige, S | 1 |
| Takahashi-Yanaga, F | 1 |
| Ishikane, S | 1 |
| Arioka, M | 1 |
| Igawa, K | 1 |
| Kuroo, A | 1 |
| Tomooka, K | 1 |
| Shiose, A | 1 |
| Sasaguri, T | 1 |
| Sadayappan, S | 3 |
| Gilbert, RJ | 1 |
| Hu, H | 1 |
| Jiang, M | 1 |
| Cao, Y | 1 |
| Zhang, Z | 2 |
| Jiang, B | 1 |
| Tian, F | 1 |
| Feng, J | 1 |
| Dou, Y | 1 |
| Gorospe, M | 1 |
| Zheng, M | 2 |
| Zheng, L | 1 |
| Yang, Z | 1 |
| Wang, W | 1 |
| Savergnini, SQ | 1 |
| Ianzer, D | 1 |
| Carvalho, MB | 1 |
| Ferreira, AJ | 1 |
| Silva, GA | 1 |
| Marques, FD | 1 |
| Peluso, AA | 1 |
| Beiman, M | 1 |
| Cojocaru, G | 1 |
| Cohen, Y | 1 |
| Almeida, AP | 1 |
| Rotman, G | 1 |
| Santos, RA | 1 |
| Huang, ZP | 1 |
| Chen, J | 3 |
| Seok, HY | 1 |
| Kataoka, M | 1 |
| Hu, X | 1 |
| Yang, C | 1 |
| Yang, H | 1 |
| Wu, J | 1 |
| Meng, Z | 1 |
| Xing, R | 1 |
| Tian, A | 1 |
| Tian, X | 1 |
| Guo, L | 1 |
| Nie, G | 1 |
| Li, Z | 2 |
| Zhong, ML | 1 |
| Wang, H | 3 |
| Zhou, HM | 1 |
| Zhang, YF | 2 |
| Cui, WY | 2 |
| Long, CL | 2 |
| Duan, L | 1 |
| Li, H | 1 |
| Lu, ZZ | 1 |
| Song, Y | 2 |
| Xiao, H | 1 |
| Belge, C | 1 |
| Hammond, J | 1 |
| Dubois-Deruy, E | 1 |
| Manoury, B | 1 |
| Hamelet, J | 1 |
| Beauloye, C | 1 |
| Markl, A | 1 |
| Pouleur, AC | 1 |
| Bertrand, L | 1 |
| Esfahani, H | 1 |
| Jnaoui, K | 1 |
| Götz, KR | 1 |
| Nikolaev, VO | 1 |
| Vanderper, A | 1 |
| Herijgers, P | 1 |
| Lobysheva, I | 1 |
| Iaccarino, G | 2 |
| Hilfiker-Kleiner, D | 1 |
| Tavernier, G | 1 |
| Langin, D | 1 |
| Dessy, C | 1 |
| Balligand, JL | 1 |
| Toldo, S | 1 |
| Mezzaroma, E | 1 |
| Bressi, E | 1 |
| Marchetti, C | 1 |
| Carbone, S | 1 |
| Sonnino, C | 1 |
| Van Tassell, BW | 1 |
| Abbate, A | 1 |
| Zhu, XQ | 1 |
| Hong, HS | 1 |
| Lin, XH | 1 |
| Chen, LL | 1 |
| Li, YH | 1 |
| Kuo, IY | 1 |
| Kwaczala, AT | 1 |
| Nguyen, L | 1 |
| Russell, KS | 1 |
| Campbell, SG | 1 |
| Ehrlich, BE | 1 |
| Parthasarathy, A | 1 |
| Gopi, V | 1 |
| Devi K M, S | 1 |
| Balaji, N | 1 |
| Vellaichamy, E | 1 |
| Repas, AA | 1 |
| Talarico, JA | 1 |
| Gold, JI | 1 |
| Carter, RL | 1 |
| Koch, WJ | 2 |
| Tilley, DG | 1 |
| Taghavi, S | 1 |
| Sharp, TE | 1 |
| Duran, JM | 1 |
| Makarewich, CA | 1 |
| Berretta, RM | 1 |
| Starosta, T | 1 |
| Kubo, H | 1 |
| Barbe, M | 1 |
| Houser, SR | 1 |
| Mnafgui, K | 3 |
| Hajji, R | 3 |
| Derbali, F | 3 |
| Khlif, I | 2 |
| Kraiem, F | 2 |
| Ellefi, H | 3 |
| Elfeki, A | 2 |
| Allouche, N | 3 |
| Gharsallah, N | 3 |
| Huang, Y | 2 |
| Dai, M | 1 |
| Du, YM | 1 |
| Yao, YF | 1 |
| Zhang, JM | 1 |
| Su, GH | 1 |
| Shu, YW | 1 |
| Cui, TP | 1 |
| Du, XL | 1 |
| Li, JD | 1 |
| Thoonen, R | 1 |
| Ernande, L | 1 |
| Cheng, J | 1 |
| Nagasaka, Y | 1 |
| Yao, V | 1 |
| Miranda-Bezerra, A | 1 |
| Chao, W | 1 |
| Panagia, M | 1 |
| Sosnovik, DE | 1 |
| Puppala, D | 1 |
| Armoundas, AA | 1 |
| Hindle, A | 1 |
| Bloch, KD | 2 |
| Buys, ES | 1 |
| Scherrer-Crosbie, M | 2 |
| Liu, M | 1 |
| Ke, J | 1 |
| Li, L | 2 |
| Huang, D | 1 |
| Wu, W | 1 |
| Michel, T | 1 |
| Halabalaki, M | 1 |
| Skaltsounis, AL | 1 |
| Grimm, M | 1 |
| Ling, H | 1 |
| Willeford, A | 1 |
| Pereira, L | 1 |
| Gray, CB | 1 |
| Erickson, JR | 1 |
| Sarma, S | 1 |
| Respress, JL | 1 |
| Wehrens, XH | 1 |
| Bers, DM | 1 |
| Brown, JH | 1 |
| Liu, B | 1 |
| Wu, Z | 1 |
| Ou, C | 1 |
| Huang, Z | 1 |
| Liu, P | 1 |
| Luo, C | 1 |
| Chen, M | 1 |
| Gammoudi, A | 1 |
| Khabbabi, G | 1 |
| Kadri, A | 1 |
| Medzikovic, L | 1 |
| Schumacher, CA | 1 |
| Verkerk, AO | 1 |
| van Deel, ED | 1 |
| Wolswinkel, R | 1 |
| van der Made, I | 1 |
| Bleeker, N | 1 |
| Cakici, D | 1 |
| van den Hoogenhof, MM | 1 |
| Meggouh, F | 1 |
| Creemers, EE | 1 |
| Remme, CA | 1 |
| Baartscheer, A | 1 |
| de Winter, RJ | 1 |
| de Vries, CJ | 1 |
| Arkenbout, EK | 1 |
| de Waard, V | 1 |
| Xu, W | 1 |
| Wang, Y | 7 |
| Zhu, X | 1 |
| Yuan, W | 1 |
| Shi, Y | 1 |
| Jiang, Z | 1 |
| Ye, X | 1 |
| Wan, Y | 2 |
| Peng, X | 1 |
| Deng, Y | 1 |
| Chen, F | 1 |
| Wang, X | 1 |
| Dai, G | 1 |
| Luo, S | 1 |
| Fan, X | 1 |
| Mo, X | 1 |
| Wu, X | 1 |
| Rau, C | 1 |
| Avetisyan, R | 1 |
| Romay, MC | 2 |
| Stolin, G | 1 |
| Gong, KW | 1 |
| Lusis, AJ | 2 |
| Sato, H | 1 |
| Suzuki, JI | 1 |
| Aoyama, N | 1 |
| Watanabe, R | 1 |
| Kaneko, M | 1 |
| Shiheido, Y | 1 |
| Yoshida, A | 1 |
| Wakayama, K | 1 |
| Kumagai, H | 1 |
| Ikeda, Y | 1 |
| Akazawa, H | 1 |
| Komuro, I | 1 |
| Isobe, M | 1 |
| Izumi, Y | 2 |
| Michel, FS | 1 |
| Magubane, M | 1 |
| Mokotedi, L | 1 |
| Ikeda, J | 1 |
| Kimoto, N | 1 |
| Kitayama, T | 1 |
| Kunori, S | 1 |
| Levitan, BM | 1 |
| Manning, JR | 1 |
| Withers, CN | 1 |
| Smith, JD | 1 |
| Shaw, RM | 1 |
| Andres, DA | 1 |
| Sorrell, VL | 1 |
| Satin, J | 1 |
| Drum, BM | 1 |
| Yin, H | 1 |
| Guo, X | 1 |
| Luckey, SW | 1 |
| Gilbert, ML | 1 |
| McKnight, GS | 1 |
| Scott, JD | 1 |
| Santana, LF | 1 |
| Liu, Q | 1 |
| Tuteryan, M | 1 |
| Santolini, M | 1 |
| Karma, A | 1 |
| Weiss, JN | 1 |
| Zhang, H | 1 |
| Zhou, R | 1 |
| Ma, P | 1 |
| Xiong, A | 1 |
| Xu, Q | 2 |
| Palfi, A | 2 |
| Bartha, E | 1 |
| Copf, L | 1 |
| Mark, L | 1 |
| Gallyas, F | 2 |
| Veres, B | 1 |
| Kalman, E | 1 |
| Pajor, L | 1 |
| Toth, K | 2 |
| Ohmacht, R | 1 |
| Sumegi, B | 2 |
| Pat, B | 2 |
| Killingsworth, C | 2 |
| Denney, T | 2 |
| Zheng, J | 1 |
| Powell, P | 1 |
| Tillson, M | 2 |
| Dillon, AR | 2 |
| Dell'Italia, LJ | 2 |
| Liu, YH | 1 |
| D'Ambrosio, M | 1 |
| Liao, TD | 1 |
| Peng, H | 1 |
| Rhaleb, NE | 1 |
| Sharma, U | 1 |
| André, S | 1 |
| Gabius, HJ | 1 |
| Carretero, OA | 1 |
| Wang, J | 2 |
| Tsukashita, M | 1 |
| Nishina, T | 1 |
| Marui, A | 1 |
| Yoshikawa, E | 1 |
| Muranaka, H | 1 |
| Matsuoka, S | 1 |
| Ikeda, T | 1 |
| Falcão-Pires, I | 1 |
| Gonçalves, N | 1 |
| Moura, C | 1 |
| Lamego, I | 1 |
| Eloy, C | 1 |
| Lopes, JM | 1 |
| Begieneman, MP | 1 |
| Niessen, HW | 1 |
| Areias, JC | 1 |
| Leite-Moreira, AF | 1 |
| Mikusová, A | 1 |
| Králová, E | 2 |
| Tylková, L | 1 |
| Novotová, M | 1 |
| Stankovicová, T | 2 |
| Molojavyi, A | 1 |
| Lindecke, A | 1 |
| Raupach, A | 1 |
| Moellendorf, S | 1 |
| Köhrer, K | 1 |
| Gödecke, A | 1 |
| Webb, IG | 1 |
| Nishino, Y | 1 |
| Clark, JE | 1 |
| Murdoch, C | 1 |
| Walker, SJ | 1 |
| Makowski, MR | 1 |
| Botnar, RM | 1 |
| Redwood, SR | 1 |
| Shah, AM | 1 |
| Marber, MS | 1 |
| Chen, CX | 2 |
| Gu, WL | 2 |
| Wu, Q | 2 |
| Lü, J | 1 |
| Gladden, JD | 1 |
| Walcott, G | 1 |
| Powell, PC | 1 |
| Gupta, H | 1 |
| Desai, R | 1 |
| Peña, JR | 1 |
| Szkudlarek, AC | 1 |
| Warren, CM | 1 |
| Heinrich, LS | 1 |
| Gaffin, RD | 1 |
| Jagatheesan, G | 1 |
| del Monte, F | 1 |
| Hajjar, RJ | 1 |
| Goldspink, PH | 1 |
| Solaro, RJ | 1 |
| Wieczorek, DF | 1 |
| Wolska, BM | 1 |
| Sharma, A | 1 |
| Mediratta, PK | 1 |
| Sharma, KK | 1 |
| Fahim, M | 1 |
| Zuo, YM | 2 |
| Cao, JF | 1 |
| Yu, HJ | 1 |
| Li, JZ | 1 |
| Peng, J | 1 |
| Xiao, L | 1 |
| Zhang, YS | 1 |
| Liao, MC | 1 |
| Li, XH | 1 |
| Hu, CP | 1 |
| Deng, HW | 1 |
| Li, YJ | 1 |
| Wang, XH | 2 |
| Lv, J | 1 |
| Song, YH | 2 |
| Cai, H | 2 |
| Gu, N | 1 |
| Qian, CF | 1 |
| Cao, SP | 1 |
| Zhao, ZM | 1 |
| Foster, CR | 1 |
| Singh, M | 2 |
| Subramanian, V | 2 |
| Singh, K | 3 |
| Soltysinska, E | 2 |
| Olesen, SP | 2 |
| Osadchii, OE | 3 |
| Ma, X | 1 |
| Fu, Y | 1 |
| Shen, Q | 1 |
| Thiele, S | 1 |
| Shibata, M | 1 |
| Takeshita, D | 1 |
| Obata, K | 1 |
| Mitsuyama, S | 1 |
| Zhang, GX | 1 |
| Takaki, M | 1 |
| Miller, CL | 1 |
| Cai, Y | 1 |
| Oikawa, M | 1 |
| Thomas, T | 1 |
| Dostmann, WR | 1 |
| Zaccolo, M | 1 |
| Fujiwara, K | 1 |
| Yan, C | 1 |
| Booysen, HL | 1 |
| Opie, LH | 1 |
| Gu, YP | 1 |
| Yuan, BP | 1 |
| Guo, W | 1 |
| Wei, HC | 1 |
| Lv, R | 1 |
| Råmunddal, T | 1 |
| Lindbom, M | 1 |
| Täng, MS | 1 |
| Shao, Y | 1 |
| Borén, J | 1 |
| Omerovic, E | 1 |
| Ueta, CB | 1 |
| Oskouei, BN | 1 |
| Olivares, EL | 1 |
| Pinto, JR | 1 |
| Correa, MM | 1 |
| Simovic, G | 1 |
| Simonides, WS | 1 |
| Hare, JM | 1 |
| Bianco, AC | 1 |
| Huang, LL | 1 |
| Yu, TT | 1 |
| Du, SM | 1 |
| Guo, YW | 1 |
| Jia, Y | 1 |
| Fan, H | 1 |
| Ren, K | 1 |
| Gu, R | 1 |
| Shen, N | 1 |
| An, Y | 1 |
| Zhong, Y | 1 |
| Verma, SK | 1 |
| Krishnamurthy, P | 2 |
| Barefield, D | 1 |
| Singh, N | 1 |
| Gupta, R | 1 |
| Lambers, E | 1 |
| Thal, M | 1 |
| Mackie, A | 1 |
| Hoxha, E | 1 |
| Ramirez, V | 1 |
| Qin, G | 1 |
| Ghosh, AK | 1 |
| Kishore, R | 1 |
| Forechi, L | 1 |
| Baldo, MP | 1 |
| Meyerfreund, D | 1 |
| Mill, JG | 1 |
| Bourgonje, VJ | 1 |
| Schoenmakers, M | 1 |
| Beekman, JD | 1 |
| van der Nagel, R | 1 |
| Houtman, MJ | 1 |
| Miedema, LF | 1 |
| Antoons, G | 1 |
| Sipido, K | 1 |
| de Windt, LJ | 1 |
| van Veen, TA | 1 |
| Vos, MA | 1 |
| Guggilam, A | 1 |
| Hutchinson, KR | 1 |
| West, TA | 1 |
| Kelly, AP | 1 |
| Galantowicz, ML | 1 |
| Davidoff, AJ | 1 |
| Lucchesi, PA | 1 |
| Uechi, M | 1 |
| Sasaki, T | 1 |
| Ueno, K | 1 |
| Yamamoto, T | 1 |
| Ishikawa, Y | 1 |
| Badenhorst, D | 2 |
| Veliotes, D | 1 |
| Maseko, M | 2 |
| Tsotetsi, OJ | 2 |
| Brooksbank, R | 1 |
| Naidoo, A | 1 |
| Yin, F | 1 |
| Chen, L | 1 |
| Chen, K | 1 |
| Wang, YY | 1 |
| Han, C | 1 |
| Hodgson, DM | 1 |
| Zingman, LV | 1 |
| Kane, GC | 1 |
| Perez-Terzic, C | 1 |
| Bienengraeber, M | 1 |
| Ozcan, C | 1 |
| Gumina, RJ | 1 |
| Pucar, D | 1 |
| O'Coclain, F | 1 |
| Mann, DL | 1 |
| Alekseev, AE | 1 |
| Terzic, A | 1 |
| Gourine, AV | 1 |
| Hu, Q | 1 |
| Sander, PR | 1 |
| Kuzmin, AI | 1 |
| Hanafy, N | 1 |
| Davydova, SA | 1 |
| Zaretsky, DV | 1 |
| Takahashi, T | 1 |
| Anzai, T | 1 |
| Yoshikawa, T | 1 |
| Maekawa, Y | 1 |
| Mahara, K | 1 |
| Iwata, M | 1 |
| Hammond, HK | 1 |
| Ogawa, S | 1 |
| Brouri, F | 1 |
| Hanoun, N | 1 |
| Mediani, O | 1 |
| Saurini, F | 1 |
| Hamon, M | 1 |
| Vanhoutte, PM | 1 |
| Lechat, P | 1 |
| Hardt, SE | 1 |
| Tomita, H | 1 |
| Katus, HA | 1 |
| Sadoshima, J | 1 |
| Janssens, S | 1 |
| Pokreisz, P | 1 |
| Schoonjans, L | 1 |
| Pellens, M | 1 |
| Vermeersch, P | 1 |
| Tjwa, M | 1 |
| Jans, P | 1 |
| Picard, MH | 1 |
| Szelid, Z | 1 |
| Gillijns, H | 1 |
| Van de Werf, F | 1 |
| Collen, D | 1 |
| Kondo, I | 1 |
| Ohmori, K | 1 |
| Oshita, A | 1 |
| Takeuchi, H | 1 |
| Fuke, S | 1 |
| Shinomiya, K | 1 |
| Noma, T | 1 |
| Namba, T | 1 |
| Kohno, M | 1 |
| Anamourlis, C | 1 |
| Gibbs, M | 1 |
| Osadchii, O | 3 |
| Veliotes, DG | 2 |
| Deftereos, DA | 1 |
| Gray, D | 1 |
| Wang, GY | 1 |
| Bergman, MR | 1 |
| Nguyen, AP | 1 |
| Turcato, S | 1 |
| Swigart, PM | 1 |
| Rodrigo, MC | 1 |
| Simpson, PC | 1 |
| Karliner, JS | 1 |
| Lovett, DH | 1 |
| Baker, AJ | 1 |
| Toth, A | 1 |
| Hanto, K | 1 |
| Deres, P | 1 |
| Szabados, E | 1 |
| Szereday, Z | 1 |
| Kulcsar, G | 1 |
| Kalai, T | 1 |
| Hideg, K | 1 |
| Halmosi, R | 1 |
| Fan, GC | 1 |
| Yuan, Q | 1 |
| Song, G | 1 |
| Chen, G | 1 |
| Zhou, X | 1 |
| Lee, YJ | 1 |
| Ashraf, M | 1 |
| Kranias, EG | 1 |
| Suto, F | 1 |
| Chan, A | 1 |
| Gross, GJ | 1 |
| Birkeland, JA | 1 |
| Sjaastad, I | 1 |
| Brattelid, T | 1 |
| Qvigstad, E | 1 |
| Moberg, ER | 1 |
| Krobert, KA | 1 |
| Bjørnerheim, R | 1 |
| Skomedal, T | 1 |
| Sejersted, OM | 1 |
| Osnes, JB | 1 |
| Levy, FO | 1 |
| Deftereos, D | 1 |
| Thomas, DP | 1 |
| Leosco, D | 1 |
| Rengo, G | 1 |
| Golino, L | 1 |
| Marchese, M | 1 |
| Fortunato, F | 1 |
| Zincarelli, C | 1 |
| Sanzari, E | 1 |
| Ciccarelli, M | 1 |
| Galasso, G | 1 |
| Altobelli, GG | 1 |
| Conti, V | 1 |
| Matrone, G | 1 |
| Cimini, V | 1 |
| Ferrara, N | 1 |
| Filippelli, A | 1 |
| Rengo, F | 1 |
| Li, BS | 1 |
| Chen, XM | 1 |
| Mokráň, T | 1 |
| Murín, J | 1 |
| Aimond, F | 1 |
| Alvarez, JL | 1 |
| Rauzier, JM | 1 |
| Lorente, P | 1 |
| Vassort, G | 1 |
| Takemoto, Y | 1 |
| Yoshiyama, M | 1 |
| Takeuchi, K | 1 |
| Omura, T | 1 |
| Komatsu, R | 1 |
| Kim, S | 1 |
| Yoshikawa, J | 1 |
| Van Kerckhoven, R | 1 |
| Kalkman, EA | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
| Prabhu, SD | 1 |
| Chandrasekar, B | 1 |
| Murray, DR | 1 |
| Freeman, GL | 1 |
| Colucci, WS | 1 |
| Sawyer, DB | 1 |
| Communal, C | 1 |
| Sprott, S | 1 |
| Lancaster, EJ | 1 |
| Mela, T | 1 |
| Chung, ES | 1 |
| Meyer, TE | 1 |
| Gallego, M | 1 |
| Espiña, L | 1 |
| Vegas, L | 1 |
| Echevarria, E | 1 |
| Iriarte, MM | 1 |
| Casis, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease[NCT02599480] | Phase 2 | 296 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| BAT as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence Pilot[NCT03793127] | 24 participants (Actual) | Interventional | 2019-01-23 | Active, not recruiting | |||
| Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia[NCT04420260] | 152 participants (Actual) | Interventional | 2021-03-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for isoproterenol and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Adrenergic overload and apoptosis in heart failure: implications for therapy.
Topics: Adrenergic beta-Agonists; Animals; Animals, Newborn; Apoptosis; Gene Expression Regulation; Heart Fa | 2000 |
152 other studies available for isoproterenol and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AM | 2021 |
Early activation of the cardiac CX3CL1/CX3CR1 axis delays β-adrenergic-induced heart failure.
Topics: Adrenergic beta-Agonists; Animals; Cell Communication; Cell Proliferation; Cells, Cultured; Chemokin | 2021 |
Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cardiovascular Agents; Disease Models, Animal; Gal | 2021 |
Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin.
Topics: Animals; beta-Arrestin 2; Blood Glucose; Diet, High-Fat; Fructose; Glucose; Heart; Insulin; Insulin | 2021 |
Metformin Prevents Low-dose Isoproterenol-induced Cardiac Dilatation and Systolic Dysfunction in Male Sprague Dawley Rats.
Topics: Animals; Dilatation; Isoproterenol; Male; Metformin; Rats; Rats, Sprague-Dawley; Ventricular Remodel | 2022 |
Aging Impairs Reverse Remodeling and Recovery of Ventricular Function after Isoproterenol-Induced Cardiomyopathy.
Topics: Aging; Animals; Cardiomyopathies; Collagen; Disease Models, Animal; Female; Fibrosis; Gene Expressio | 2021 |
Pinocembrin mediates antiarrhythmic effects in rats with isoproterenol-induced cardiac remodeling.
Topics: Animals; Flavanones; Hydrogen Peroxide; Isoproterenol; Myocytes, Cardiac; NF-E2-Related Factor 2; Ox | 2022 |
Cardiac-specific Trim44 knockout in rat attenuates isoproterenol-induced cardiac remodeling via inhibition of AKT/mTOR pathway.
Topics: Animals; Cardiomegaly; Isoproterenol; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; TOR Se | 2023 |
Echinacoside inhibited cardiomyocyte pyroptosis and improved heart function of HF rats induced by isoproterenol via suppressing NADPH/ROS/ER stress.
Topics: Animals; Glycosides; Heart Failure; Isoproterenol; Myocytes, Cardiac; NADP; Pyroptosis; Rats; Reacti | 2022 |
Set7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Fibrosis; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Mi | 2022 |
Ablation of CXCR4 expression in cardiomyocytes exacerbates isoproterenol‑induced cell death and heart failure.
Topics: Animals; Apoptosis; Cell Death; Heart Failure; Isoproterenol; Mice; Mice, Knockout; Myocardium; Myoc | 2023 |
Toll-like receptor-2 in cardiomyocytes and macrophages mediates isoproterenol-induced cardiac inflammation and remodeling.
Topics: Adaptor Proteins, Signal Transducing; Animals; Arrhythmias, Cardiac; Heart Failure; Inflammation; Is | 2023 |
Engeletin mediates antiarrhythmic effects in mice with isoproterenol-induced cardiac remodeling.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Cardiac; Atrial Remodeling; Glutathione; | 2023 |
Anti-inflammatory, cardioprotective effect of gypenoside against isoproterenol-induced cardiac remodeling in rats via alteration of inflammation and gut microbiota.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cytokines; Gastrointestinal Microbiome; | 2023 |
Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arbutin; Atrial Natriuretic Factor; Cardiomegaly; C | 2020 |
Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats.
Topics: Animals; Berberine; Cardiomyopathies; Cell Transdifferentiation; Cells, Cultured; Coculture Techniqu | 2019 |
[Role of apoptosis signal-regulating kinase 1 in left ventricular remodeling in mice].
Topics: Animals; Isoproterenol; MAP Kinase Kinase Kinase 5; Mice; Myocardium; Myocytes, Cardiac; Ventricular | 2019 |
CD47 Deficiency Attenuates Isoproterenol-Induced Cardiac Remodeling in Mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; CD47 Antigen; Isoproterenol; Male; Mice; Mice, Inbred C57 | 2019 |
The aqueous extract of Gentianella acuta improves isoproterenol‑induced myocardial fibrosis via inhibition of the TGF‑β1/Smads signaling pathway.
Topics: Actins; Animals; Collagen; Fibrosis; Gentianella; Isoproterenol; Male; Models, Biological; Myocardiu | 2020 |
Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling.
Topics: Animals; Cardiomegaly; Fibrosis; Heart Failure; Humans; Isoproterenol; Leupeptins; Lysine; Male; Mic | 2020 |
Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Chronic Disease; Echocardiography; Heart Failure; Hydroxy | 2020 |
Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Topics: Adrenergic beta-Agonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease | 2020 |
Resveratrol prevents ISO-induced myocardial remodeling associated with regulating polarization of macrophages through VEGF-B/AMPK/NF-kB pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Isoproterenol; Macrophages; Male; Mice; Mice, Inb | 2020 |
Manipulation of beta-adrenergic receptor in pressure-overloaded murine hearts mimics adverse and reverse cardiac remodeling.
Topics: Adrenergic beta-Agonists; Animals; Disease Models, Animal; Heart; Heart Failure; Isoproterenol; Mice | 2020 |
Deletion of Microfibrillar-Associated Protein 4 Attenuates Left Ventricular Remodeling and Dysfunction in Heart Failure.
Topics: Adrenergic beta-Agonists; Animals; Aorta; Biomechanical Phenomena; Cardiomegaly; Carrier Proteins; C | 2020 |
Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Heart Failure; Isoproterenol; Ivabradine; Male; | 2021 |
Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.
Topics: Animals; Disease Models, Animal; Fibrosis; Flavonoids; Hypertrophy, Left Ventricular; Isoproterenol; | 2021 |
Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents; Cells, Cultured; Disease Models, Animal; E | 2021 |
MBNL1 regulates isoproterenol-induced myocardial remodelling in vitro and in vivo.
Topics: 3' Untranslated Regions; Animals; Animals, Newborn; Apoptosis; Base Sequence; Cardiomegaly; Disease | 2021 |
Echinacoside reverses myocardial remodeling and improves heart function via regulating SIRT1/FOXO3a/MnSOD axis in HF rats induced by isoproterenol.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Forkhead Box Protein O3; Glycogen; Glycosides; Heart Fa | 2021 |
Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
Topics: Animals; Animals, Newborn; Aorta, Abdominal; Cardiomegaly; Constriction, Pathologic; Disease Models, | 2021 |
Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'.
Topics: Adaptation, Physiological; Animals; Isoproterenol; Male; Mice; Models, Biological; Receptors, Adrene | 2021 |
Immune cell β
Topics: Adoptive Transfer; Animals; Bone Marrow Transplantation; Cell Death; Cell Proliferation; Cells, Cult | 2021 |
Coenzyme Q10 prevents oxidative stress and fibrosis in isoprenaline induced cardiac remodeling in aged rats.
Topics: Aging; Animals; Fibrosis; Isoproterenol; Male; Oxidative Stress; Rats; Rats, Long-Evans; Ubiquinone; | 2017 |
Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.
Topics: Animals; Cell Survival; Cells, Cultured; Echocardiography; Fibrosis; Gene Expression; Heart Diseases | 2017 |
Specific α7 nicotinic acetylcholine receptor agonist ameliorates isoproterenol-induced cardiac remodelling in mice through TGF-β1/Smad3 pathway.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzamides; Bridged Bicyclo Compounds; Cardiomegal | 2017 |
Oligomeric proanthocyanidins protect myocardium by mitigating left ventricular remodeling in isoproterenol-induced postmyocardial infarction.
Topics: Animals; Antioxidants; Bone Morphogenetic Protein 4; Cardiovascular Agents; Collagen; Disease Models | 2018 |
[Huangqi Danshen decoction attenuates isoproterenol-induced myocardial remodeling via STIM1, TRPC1, CaN and NFATc3 pathways in rats].
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Drugs, Chinese Herbal; Heart; Isoproter | 2017 |
Resident fibroblast expansion during cardiac growth and remodeling.
Topics: Animals; Animals, Newborn; Basic Helix-Loop-Helix Transcription Factors; Cell Line; Cell Lineage; Ce | 2018 |
Effect of Atractylodes macrocephala rhizoma on isoproterenol‑induced ventricular remodeling in rats.
Topics: Animals; Antioxidants; Atractylodes; Biomarkers; Heart Ventricles; Hemodynamics; Isoproterenol; Male | 2018 |
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Disease Models, Anima | 2019 |
Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Echocardiography; Female; Heart Failure; Iso | 2018 |
Quantitative temporal analysis of protein dynamics in cardiac remodeling.
Topics: Animals; Heart; Heart Failure; Humans; Isoproterenol; Mice; Myocardium; Protein Biosynthesis; Proteo | 2018 |
Anti-fibrotic Actions of Roselle Extract in Rat Model of Myocardial Infarction.
Topics: Animals; Atrial Natriuretic Factor; Cardiovascular Agents; Collagen Type I; Collagen Type III; Disea | 2019 |
[Effects of Scrophulariae Radix and Split Component on Isoproterenol-Induced Ventricular Remodeling in Rat].
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Endothelin-1; Isoproterenol; Myocardium; Plant R | 2016 |
Fasting/Refeeding Cycles Prevent Myocardial Dysfunction and Morphology Damage in the Spontaneously Hypertensive Rats.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Calcium; Caloric Restriction; Card | 2018 |
Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model.
Topics: Animals; Cardiomegaly; Dimethyl Fumarate; Disease Models, Animal; Extracellular Signal-Regulated MAP | 2018 |
Role of type 2A phosphatase regulatory subunit B56α in regulating cardiac responses to β-adrenergic stimulation in vivo.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Disease Models, Animal; Dobutamine; Female; Heart R | 2019 |
Limited Impact of β-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease.
Topics: Adrenergic beta-Agonists; Animals; Diastole; Disease Models, Animal; Echocardiography, Doppler, Puls | 2018 |
Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cytokines; Disease Models, Animal; Fibr | 2018 |
Linagliptin Suppresses Electrical and Structural Remodeling in the Isoproterenol Induced Myocardial Injury Model.
Topics: Animals; Antioxidants; Atrial Remodeling; Cardiotonic Agents; Dipeptidyl Peptidase 4; Dipeptidyl-Pep | 2019 |
2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.
Topics: 2-Methoxyestradiol; Angiotensin II; Animals; Blood Pressure; Fibrosis; Glomerular Filtration Rate; H | 2019 |
Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Collagen Type I; Collagen Type III; Disease Models, Animal; Fibrosis; | 2019 |
Transient inhibition of neddylation at neonatal stage evokes reversible cardiomyopathy and predisposes the heart to isoproterenol-induced heart failure.
Topics: Animals; Animals, Newborn; Cell Proliferation; Cells, Cultured; Cyclopentanes; Disease Models, Anima | 2019 |
Relations between markers of cardiac remodelling and left ventricular collagen in an isoproterenol-induced heart damage model.
Topics: Animals; Blood Pressure; Collagen; Heart Failure; Heart Ventricles; Isoproterenol; Male; Peptide Fra | 2019 |
Effects of regular exercise plus food restriction on left ventricular pathological remodeling in heart failure‑induced rats.
Topics: Animals; Caloric Restriction; Heart; Heart Failure; Heart Ventricles; Isoproterenol; Male; Myocardiu | 2019 |
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
Topics: Animals; Animals, Newborn; Cardiomegaly; Disease Models, Animal; Fibroblasts; Glycogen Synthase Kina | 2019 |
The potential role of neddylation in pre- and postnatal cardiac remodeling.
Topics: Cardiomyopathies; Heart Failure; Humans; Infant, Newborn; Isoproterenol; Signal Transduction; Ventri | 2019 |
HuR regulates phospholamban expression in isoproterenol-induced cardiac remodelling.
Topics: Animals; Calcium Signaling; Calcium-Binding Proteins; Cell Line; Disease Models, Animal; ELAV-Like P | 2020 |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; CHO Cells; Collagen; Cricetinae; Cricetulus; Fibronectins | 2013 |
MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.
Topics: Amino Acid Sequence; Animals; Calcineurin; Cardiomegaly; Cardiomyopathy, Dilated; Disease Models, An | 2013 |
No overt structural or functional changes associated with PEG-coated gold nanoparticles accumulation with acute exposure in the mouse heart.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cardiotoxins; Disease Models, Animal; Drug Delivery | 2013 |
[Effects of ATP-sensitive potassium channel opener iptakalim against ventricular remodeling and its mechanisms of endothelial protection].
Topics: Animals; Endothelin-1; Hemodynamics; Hydroxyproline; Isoproterenol; KATP Channels; Male; Myocardium; | 2013 |
Echocardiographic assessment of β-adrenoceptor stimulation-induced heart failure with reduced heart rate in mice.
Topics: Adrenergic beta-Agonists; Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Echocardiography | 2014 |
Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase.
Topics: Angiotensin II; Animals; Cells, Cultured; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Disease | 2014 |
Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse.
Topics: Animals; Antibodies, Monoclonal; Disease Models, Animal; Echocardiography; Interleukin-1beta; Isopro | 2014 |
Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide.
Topics: Aldosterone; Animals; Cardiotonic Agents; Chronic Disease; Collagen; Cytochrome P-450 CYP11B2; Disea | 2014 |
Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Caffeine; Calcium Si | 2014 |
Aminoguanidine inhibits ventricular fibrosis and remodeling process in isoproterenol-induced hypertrophied rat hearts by suppressing ROS and MMPs.
Topics: Animals; Antioxidants; Cardiomegaly; Fibrosis; Guanidines; Heart Ventricles; Isoproterenol; Male; Ma | 2014 |
Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cells, Cultured; Chemokine CCL2; ErbB Re | 2015 |
Autologous c-Kit+ Mesenchymal Stem Cell Injections Provide Superior Therapeutic Benefit as Compared to c-Kit+ Cardiac-Derived Stem Cells in a Feline Model of Isoproterenol-Induced Cardiomyopathy.
Topics: Animals; Biomarkers; Cardiomyopathies; Cats; Cell Proliferation; Cells, Cultured; Disease Models, An | 2015 |
Protective Effect of Hydroxytyrosol Against Cardiac Remodeling After Isoproterenol-Induced Myocardial Infarction in Rat.
Topics: Animals; Cardiotonic Agents; Isoproterenol; Male; Myocardial Infarction; Phenylethyl Alcohol; Rats; | 2016 |
[Combined transgenic inhibition of CaMKII and Ik1 on cardiac remodeling].
Topics: Animals; Arrhythmias, Cardiac; Brugada Syndrome; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2015 |
Functional brown adipose tissue limits cardiomyocyte injury and adverse remodeling in catecholamine-induced cardiomyopathy.
Topics: Adipose Tissue, Brown; Animals; Biomarkers; Blood Pressure; Body Weight; Cardiomyopathies; Cardioton | 2015 |
Triptolide alleviates isoprenaline-induced cardiac remodeling in rats via TGF-β1/Smad3 and p38 MAPK signaling pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiotonic Agents; Diterpenes; Ep | 2015 |
Preventive effects of oleuropein against cardiac remodeling after myocardial infarction in Wistar rat through inhibiting angiotensin-converting enzyme activity.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Dose-Response Relations | 2015 |
CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca(2+) leak and the pathophysiological response to chronic β-adrenergic stimulation.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Calcium Signaling; Calcium-Binding Proteins; Calcium-Cal | 2015 |
Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy.
Topics: Adenine; AMP-Activated Protein Kinases; Animals; Autophagy; Cardiomegaly; Carrier Proteins; Disease | 2015 |
Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarker | 2016 |
Orphan nuclear receptor Nur77 affects cardiomyocyte calcium homeostasis and adverse cardiac remodelling.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Heart Failure; Homeostasis; Humans; Isoproterenol; Mice; | 2015 |
Cardiac Specific Overexpression of hHole Attenuates Isoproterenol-Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Humans; Intracellular Signaling Peptides an | 2016 |
Genetic Dissection of Cardiac Remodeling in an Isoproterenol-Induced Heart Failure Mouse Model.
Topics: Animals; Disease Models, Animal; Echocardiography; Galectin 3; Gene Expression Regulation; Heart Fai | 2016 |
A Periodontal pathogen Porphyromonas gingivalis deteriorates Isoproterenol-Induced myocardial remodeling in mice.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Disease Models, Animal; Heart; Isoproterenol; Mice, | 2017 |
Sex-Specific Effects of Adrenergic-Induced Left Ventricular Remodeling in Spontaneously Hypertensive Rats.
Topics: Adrenergic Agents; Animals; Cells, Cultured; Disease Models, Animal; Female; Isoproterenol; Male; My | 2017 |
Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats.
Topics: Adamantane; Animals; Diastole; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitor | 2016 |
Rad-deletion Phenocopies Tonic Sympathetic Stimulation of the Heart.
Topics: Animals; Calcium Channels, L-Type; Cardiomegaly; Case-Control Studies; Echocardiography, Stress; Gen | 2016 |
Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve.
Topics: A Kinase Anchor Proteins; Animals; Calcineurin; Calcium Signaling; Calcium-Binding Proteins; Cardiom | 2017 |
Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice.
Topics: ADAMTS Proteins; Animals; Cardiomegaly; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Gene E | 2017 |
Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.
Topics: Allyl Compounds; Animals; Dose-Response Relationship, Drug; Endothelial Cells; Glyburide; Heart Fail | 2017 |
Protective effects of low-dose rosuvastatin on isoproterenol-induced chronic heart failure in rats by regulation of DDAH-ADMA-NO pathway.
Topics: Amidohydrolases; Animals; Biomarkers; Cardiotonic Agents; Disease Models, Animal; Fibrosis; Heart Fa | 2017 |
Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C alpha/beta II.
Topics: Animals; Cardiotonic Agents; Isoproterenol; Male; Phosphorylation; Protein Kinase C; Protein Kinase | 2009 |
Dissociation between cardiomyocyte function and remodeling with beta-adrenergic receptor blockade in isolated canine mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anima | 2008 |
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Topics: Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Cardio | 2009 |
Chronic partial unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in failing rat hearts.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Gene Expression; Heart Failure; Heart Transplan | 2009 |
Effects of diabetes mellitus, pressure-overload and their association on myocardial structure and function.
Topics: Adrenergic beta-Agonists; Animals; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Experimenta | 2009 |
Myocardial remodelling induced by repeated low doses of isoproterenol.
Topics: Animals; Cardiotonic Agents; Drug Administration Schedule; Hemodynamics; Hypertrophy, Left Ventricul | 2009 |
Myoglobin-deficient mice activate a distinct cardiac gene expression program in response to isoproterenol-induced hypertrophy.
Topics: Adaptation, Physiological; Animals; Cluster Analysis; Disease Models, Animal; Gene Expression Profil | 2010 |
Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Enz | 2010 |
Effects of polydatin on attenuating ventricular remodeling in isoproterenol-induced mouse and pressure-overload rat models.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Cardiovascular Agents; Colla | 2010 |
Mast cell stabilization decreases cardiomyocyte and LV function in dogs with isolated mitral regurgitation.
Topics: Adrenergic beta-Agonists; Analysis of Variance; Animals; Anti-Allergic Agents; Collagen; Dogs; Extra | 2010 |
Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy.
Topics: Actin Cytoskeleton; Adenoviridae; Animals; Animals, Newborn; Atrial Natriuretic Factor; Calcium-Bind | 2010 |
Lipotab, a polyherbal formulation, attenuates isoprenaline-induced left ventricular remodeling and heart failure in rats.
Topics: Administration, Oral; Animals; Antioxidants; Body Weight; Disease Models, Animal; Female; Glutathion | 2011 |
[Effects of oligomeric grape seed proanthocyanidins on isoproterenol-induced cardiac remodeling in rats].
Topics: Animals; Antioxidants; Grape Seed Extract; Heart Rate; Hydroxyproline; Isoproterenol; Male; Malondia | 2010 |
Reversal of isoprenaline-induced cardiac remodeling by rutaecarpine via stimulation of calcitonin gene-related peptide production.
Topics: Animals; Apoptosis; Body Weight; Calcitonin Gene-Related Peptide; Echocardiography; Ganglia, Spinal; | 2010 |
Oligomerized grape seed proanthocyanidins ameliorates isoproterenol-induced cardiac remodeling in rats: role of oxidative stress.
Topics: Animals; Antioxidants; Cardiotonic Agents; Cyclooxygenase 2; Disease Models, Animal; Grape Seed Extr | 2011 |
[Effect of Chrysanthemum indicum on ventricular remodeling in rats].
Topics: Aldosterone; Angiotensin II; Animals; Chrysanthemum; Disease Models, Animal; Drugs, Chinese Herbal; | 2010 |
Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Cardiotonic Agents; Disease Models, Animal; Down-Regulation; Fla | 2011 |
Ataxia telangiectasia mutated kinase plays a protective role in β-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associat | 2011 |
Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Cardiomyopathies; Disease Models, Animal; Guin | 2011 |
Distinct actions of intermittent and sustained β-adrenoceptor stimulation on cardiac remodeling.
Topics: Adrenergic beta-Agonists; Animals; Echocardiography; Fibrosis; Heart Rate; Hypertrophy; Infusion Pum | 2011 |
Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channels, L-Type; Colforsin; Cyclic AMP; Down-Regulation; | 2011 |
NHE-1 participates in isoproterenol-induced downregulation of SERCA2a and development of cardiac remodeling in rat hearts.
Topics: Animals; Calcium Signaling; Calcium-Binding Proteins; Cardiomegaly; Collagen; Disease Models, Animal | 2011 |
Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Cyclic Nucleotide Phosphodiesterases, Type 1; | 2011 |
Reverse chamber remodelling following adrenergic-induced advanced cardiac dilatation and pump dysfunction.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomyopathy, Dilated; Isoproterenol; Male; Myocytes | 2012 |
[Protective effects of Leonurus japonicas on myocardial remodeling induced by isoproterenol in rats].
Topics: Animals; Antioxidants; Collagen; Disease Models, Animal; Hemodynamics; Hydroxyproline; Immunohistoch | 2011 |
Overexpression of apolipoprotein B attenuates pathologic cardiac remodeling and hypertrophy in response to catecholamines and after myocardial infarction in mice.
Topics: Animals; Apolipoproteins B; Cardiomegaly; Echocardiography; Heart; Humans; Isoproterenol; Male; Mice | 2012 |
Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice.
Topics: Animals; Animals, Newborn; Cardiomyopathy, Restrictive; Cardiotonic Agents; Dose-Response Relationsh | 2012 |
[Effects of a compound Chinese medicine Xinji' erkang on isoproterenol-induced ventricular remodeling in mice].
Topics: Animals; Drugs, Chinese Herbal; Isoproterenol; Male; Malondialdehyde; Mice; Mice, Inbred Strains; Ox | 2012 |
[Inhibitory effect and mechanism of procyanidin from vaccinium on isoprenaline-induced myocardial fibrosis in rats].
Topics: Angiotensins; Animals; Antioxidants; Biflavonoids; Catechin; Endomyocardial Fibrosis; Female; Isopro | 2012 |
Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Disease Susceptibility; Fibrosis; Interleukin-10; Iso | 2012 |
Granulocyte colony-stimulating factor improves early remodeling in isoproterenol-induced cardiac injury in rats.
Topics: Animals; Collagen; Dilatation, Pathologic; Disease Models, Animal; Echocardiography; Fibrosis; Granu | 2012 |
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Topics: Animals; Arrhythmias, Cardiac; Atrioventricular Block; Benzylamines; Calcineurin; Calcium-Binding Pr | 2012 |
In vivo and in vitro cardiac responses to beta-adrenergic stimulation in volume-overload heart failure.
Topics: Adrenergic beta-Agonists; Animals; Calcium Signaling; Cells, Cultured; Connexin 43; Extracellular Si | 2013 |
Cardiovascular and renal effects of carvedilol in dogs with heart failure.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Agoni | 2002 |
Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Body Weight; Collagen; Dilatation, Pathologic; Di | 2003 |
Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart.
Topics: Adrenergic beta-Agonists; Animals; Antibodies; Cells, Cultured; Cyclic AMP; DNA-Binding Proteins; Fi | 2003 |
Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance.
Topics: Adenosine Triphosphate; Animals; Calcium; Cardiac Output, Low; Cardiotonic Agents; Creatine Kinase; | 2003 |
Interstitial purine metabolites in hearts with LV remodeling.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Blood Pressure; Cardiac Output; Heart Rate; He | 2004 |
Angiotensin receptor blockade improves myocardial beta-adrenergic receptor signaling in postinfarction left ventricular remodeling: a possible link between beta-adrenergic receptor kinase-1 and protein kinase C epsilon isoform.
Topics: Adrenergic beta-Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Isoproterenol; Male; Myo | 2004 |
Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Recep | 2004 |
Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy.
Topics: Adenoviridae; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Atri | 2004 |
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Topics: Adrenergic beta-Agonists; Animals; Enzyme Induction; Fibrosis; Humans; Hypertrophy; Hypertrophy, Lef | 2004 |
Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction.
Topics: Animals; Capillaries; Cicatrix; Disease Models, Animal; Gene Expression Regulation; Gene Transfer Te | 2004 |
A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension.
Topics: Adrenergic beta-Agonists; Animals; Collagen; Dilatation, Pathologic; Drug Therapy, Combination; Echo | 2004 |
Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.
Topics: Adrenergic beta-Agonists; Animals; Collagen; Echocardiography; Heart; Hypertension; Hypertrophy, Lef | 2005 |
Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility.
Topics: Actin Cytoskeleton; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Calcium; Colforsin; Ele | 2006 |
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Topics: Animals; Cardiomegaly; Collagen Type III; Electrocardiography; Enzyme Inhibitors; Glycogen Synthase | 2006 |
Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Dow | 2006 |
IKr and IKs remodeling differentially affects QT interval prolongation and dynamic adaptation to heart rate acceleration in bradycardic rabbits.
Topics: Adaptation, Physiological; Adrenergic beta-Agonists; Animals; Bradycardia; Down-Regulation; Heart Bl | 2007 |
Effects of treatment with a 5-HT4 receptor antagonist in heart failure.
Topics: Adrenergic beta-Agonists; Animals; Cardiac Output; Heart Failure; Indoles; Isoproterenol; Lung; Male | 2007 |
Beta1 integrins modulate beta-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiac Output, Low; Echocardiography; Extracellular S | 2007 |
Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats.
Topics: Adrenergic beta-Agonists; Animals; Disease Models, Animal; Heart Ventricles; Isoproterenol; Male; My | 2007 |
Susceptibility to systolic dysfunction in the myocardium from chronically infarcted spontaneously hypertensive rats.
Topics: Animals; Apoptosis; Cardiotonic Agents; Coronary Vessels; Disease Models, Animal; Hypertension; Isop | 2008 |
Exercise promotes angiogenesis and improves beta-adrenergic receptor signalling in the post-ischaemic failing rat heart.
Topics: Adrenergic beta-Agonists; Animals; Coronary Circulation; Coronary Vessels; Disease Models, Animal; D | 2008 |
Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure.
Topics: Animals; Apoptosis; Chromatography, High Pressure Liquid; Cytokines; Down-Regulation; Epimedium; Eth | 2008 |
Electrocardiography in two models of isoproterenol-induced left ventricular remodeling.
Topics: Action Potentials; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiog | 2008 |
Ionic basis of ventricular arrhythmias in remodeled rat heart during long-term myocardial infarction.
Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Analysis of Variance; Animal | 1999 |
Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling.
Topics: Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; DNA-Binding Proteins; Echocardiography; Gene Ex | 1999 |
Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts.
Topics: Adrenergic beta-Agonists; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal | 2000 |
beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.
Topics: Adrenergic beta-Antagonists; Animals; Cytokines; Gene Expression; Interleukin-1; Interleukin-6; Isop | 2000 |
Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal; Body Weight; Captopril; Collage | 2001 |
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Collagen | 2001 |